Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 2/20 | 0.52 |
| ▸ | FPR2 | P25090 | 1/20 | 0.51 |
| ▸ | ACE | P12821 | 7/20 | 0.48 |
| ▸ | MME | P08473 | 4/20 | 0.48 |
| ▸ | CPA1 | P15085 | 4/20 | 0.48 |
| ▸ | ACE2 | Q9BYF1 | 4/20 | 0.48 |
| ▸ | NPY1R | P25929 | 1/20 | 0.45 |
| ▸ | NPY2R | P49146 | 1/20 | 0.45 |
| ▸ | NPY4R | P50391 | 1/20 | 0.45 |
| ▸ | BACE1 | P56817 | 1/20 | 0.44 |
| ▸ | CTSK | P43235 | 1/20 | 0.44 |
| ▸ | MMP1 | P03956 | 1/20 | 0.43 |
| ▸ | MMP3 | P08254 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8267315 | 0.92 | CTSL (0.52) | CTSLFPR2ACEMMECPA1 | |
| SCHEMBL21793845 | 0.89 | ACE (0.53) | FPR2ACEMMECPA1ACE2 | |
| SCHEMBL17948645 | 0.82 | LTA4H (0.58) | MMENPY1RNPY2RNPY4RBACE1 | |
| SCHEMBL21793846 | 0.82 | CYP3A4 (0.62) | — | |
| Hydrochloric Acid SCHEMBL19741503 | 0.81 | LTA4H (0.57) | MMENPY1RNPY2RNPY4RBACE1 | |
| Hydrochloric Acid SCHEMBL19741504 | 0.81 | LTA4H (0.57) | MMENPY1RNPY2RNPY4RBACE1 | |
| SCHEMBL20284364 | 0.81 | ACE (0.54) | FPR2ACEMMECPA1ACE2 | |
| SCHEMBL8266322 | 0.81 | ACE (0.54) | FPR2ACEMMECPA1ACE2 | |
| SCHEMBL10129680 | 0.81 | MMP3 (0.54) | ACEMMECPA1ACE2NPY1R | |
| SCHEMBL22503664 | 0.80 | ACE (0.59) | CTSLACEMMECPA1ACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200071356-A1 | COMPOUNDS FOR PROTEASOME | PROTEOLIX, INC. | 2020-03-05 | — | — | US | disclosed |
| US-20180170962-A1 | COMPOUNDS FOR PROTEASOME ENZYME INHIBITION | ONYX THERAPEUTICS INC (US) | 2018-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180170962-A1 | COMPOUNDS FOR PROTEASOME ENZYME INHIBITION | PSMB1, PSMB9, PSMB3 | CTSL 372/4885FPR2 1197/4885ACE 347/4885 |
| US-20200071356-A1 | COMPOUNDS FOR PROTEASOME | PSMB1, PSMB9, PSMB2 | CTSL 472/4885FPR2 1057/4885ACE 918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.